.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,566,343

« Back to Dashboard

Details for Patent: 6,566,343

Title: High affinity nucleic acid ligands of complement system proteins
Abstract:Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
Inventor(s): Biesecker; Gregory (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jan 03, 2002
Application Number:10/037,282
Claims:1. A method for treating a Complement System-mediated disease comprising administering to a patient in need thereof a pharmaceutically effective amount of a Nucleic Acid Ligand of a Complement System Protein, wherein said Nucleic Acid Ligand is selected from the group consisting of SEQ ID NOS:5-155.

2. A method of treating an infection caused by bacterial or viral cells comprising: a) conjugating a Nucleic Acid Ligand that has been generated to a bacterial cell surface target of said bacteria or viral particle target of said virus with a C1q Nucleic Acid Ligand; and b) administering the conjugate to a patient in need thereof in an amount effective to activate the Complement System and lyse the bacterial or viral cells.

3. A method of killing tumor cells in a patient comprising: a) conjugating a Nucleic Acid Ligand that has been generated to a tumor cell surface target with a C1q Nucleic Acid Ligand; and b) administering the conjugate to the patient in need thereof in an amount effective to activate the Complement System and kill the tumor or tumor cell.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc